

## Accepted Manuscript

Title: Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities

Authors: Vibhuti Agrahari, Vivek Agrahari

PII: S1359-6446(17)30229-5  
DOI: <https://doi.org/10.1016/j.drudis.2018.01.047>  
Reference: DRUDIS 2180

To appear in:



Please cite this article as: Agrahari, Vibhuti, Agrahari, Vivek, Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities. Drug Discovery Today <https://doi.org/10.1016/j.drudis.2018.01.047>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities

Vibhuti Agrahari<sup>1,§</sup> and Vivek Agrahari<sup>2,§,\*</sup>

<sup>1</sup>Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA 22601, USA

<sup>2</sup>School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO 64108, USA

\**Corresponding author:* Agrahari, V. (vahw2@mail.umkc.edu).

§Authors contributed equally.

### Highlights:

- Clinical translation and commercialization challenges of nanomedicine products
- Manufacturing or scale-up, characterization, safety, stability and efficacy hurdles
- Impediment of inadequate regulation and socioeconomic acceptance of nanomedicines
- Microfluidics QbD and PAT technologies to accelerate the nanomedicines discovery

*Teaser:* Understanding of fundamental, characterization, clinical and regulatory aspects of nanomedicines is vital to enhance their translational potential. Hence, challenges and opportunities related to the commercialization of nanomedicines are discussed.

There are numerous hurdles hindering the clinical translation of nanomedicines. The major challenges are: reproducible manufacturing and scale-up, availability of appropriate characterization methods, instability under *in vivo* environments, safety issues, poor understanding of the disease heterogeneity and patient preselection strategies, regulatory barriers and inadequate understanding of the biophysical and chemical interactions of nanoformulations. Technologies such as quality-by-design, process analytical techniques and microfluidics could significantly accelerate the translation of nanomedicines. However, these approaches require further learning and an adequate regulatory background. Overall, to achieve an efficient clinical translation, collaboration among academia, industry and regulatory bodies

Download English Version:

<https://daneshyari.com/en/article/8409625>

Download Persian Version:

<https://daneshyari.com/article/8409625>

[Daneshyari.com](https://daneshyari.com)